메뉴 건너뛰기




Volumn 6, Issue MAY, 2015, Pages

The role of the insulin/IGF system in cancer: Lessons learned from clinical trials and the energy balance-cancer link

Author keywords

Biomarkers; Energy balance; Insulin; Insulin like growth factor; Obesity

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL) AMINO] PYRROLO [2, 1 F] [1, 2, 4] TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; AVE 1642; BINDING PROTEIN; C PEPTIDE; CIXUTUMUMAB; DALOTUZUMAB; DUSIGITUMAB; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIGAND; LINSITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; R 1507; ROBATUMUMAB; SOMATOMEDIN; SOMATOMEDIN B RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

EID: 84930939846     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00077     Document Type: Review
Times cited : (123)

References (206)
  • 1
    • 79951968328 scopus 로고    scopus 로고
    • Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study
    • Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol (2011) 29:47-53. doi: 10.1200/JCO.2010.28.4752
    • (2011) J Clin Oncol , vol.29 , pp. 47-53
    • Irwin, M.L.1    Duggan, C.2    Wang, C.Y.3    Smith, A.W.4    McTiernan, A.5    Baumgartner, R.N.6
  • 2
    • 58249092146 scopus 로고    scopus 로고
    • Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
    • Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol (2009) 27:176-85. doi:10.1200/JCO.2008.17.9945
    • (2009) J Clin Oncol , vol.27 , pp. 176-185
    • Wolpin, B.M.1    Meyerhardt, J.A.2    Chan, A.T.3    Ng, K.4    Chan, J.A.5    Wu, K.6
  • 3
    • 54349083481 scopus 로고    scopus 로고
    • Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
    • Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 9:1039-47. doi:10.1016/S1470-2045(08)70235-3
    • (2008) Lancet Oncol , vol.9 , pp. 1039-1047
    • Ma, J.1    Li, H.2    Giovannucci, E.3    Mucci, L.4    Qiu, W.5    Nguyen, P.L.6
  • 4
    • 47349117519 scopus 로고    scopus 로고
    • Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies
    • Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem (2008) 114:63-70. doi:10.1080/13813450801954451
    • (2008) Arch Physiol Biochem , vol.114 , pp. 63-70
    • Pisani, P.1
  • 5
    • 1942436958 scopus 로고    scopus 로고
    • Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
    • Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 363:1346-53. doi:10.1016/S0140-6736(04)16044-3
    • (2004) Lancet , vol.363 , pp. 1346-1353
    • Renehan, A.G.1    Zwahlen, M.2    Minder, C.3    O'Dwyer, S.T.4    Shalet, S.M.5    Egger, M.6
  • 6
    • 84905867935 scopus 로고    scopus 로고
    • Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer
    • Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol (2014) 32:2059-66. doi:10.1200/JCO.2013.54.4932
    • (2014) J Clin Oncol , vol.32 , pp. 2059-2066
    • Langer, C.J.1    Novello, S.2    Park, K.3    Krzakowski, M.4    Karp, D.D.5    Mok, T.6
  • 7
    • 84930946251 scopus 로고    scopus 로고
    • Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
    • Scagliotti GV, Bondarenko I, Blackhall F, Barlesi F, Hsia TC, Jassem J, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol (2015) 26:497-504. doi:10.1093/annonc/mdu517
    • (2015) Ann Oncol , vol.26 , pp. 497-504
    • Scagliotti, G.V.1    Bondarenko, I.2    Blackhall, F.3    Barlesi, F.4    Hsia, T.C.5    Jassem, J.6
  • 8
    • 84857640868 scopus 로고    scopus 로고
    • The insulin and insulin-like growth factor receptor family in neoplasia: an update
    • Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 12:159-69. doi:10.1038/nrc3215
    • (2012) Nat Rev Cancer , vol.12 , pp. 159-169
    • Pollak, M.1
  • 9
    • 84863900275 scopus 로고    scopus 로고
    • Insulin-like growth factor receptor inhibitors: baby or the bathwater?
    • Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst (2012) 104:975-81. doi:10.1093/jnci/djs258
    • (2012) J Natl Cancer Inst , vol.104 , pp. 975-981
    • Yee, D.1
  • 10
    • 0020315756 scopus 로고
    • The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor
    • Massague J, Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem (1982) 257:5038-45.
    • (1982) J Biol Chem , vol.257 , pp. 5038-5045
    • Massague, J.1    Czech, M.P.2
  • 11
    • 34047174592 scopus 로고    scopus 로고
    • The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer
    • Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des (2007) 13:671-86. doi:10.2174/138161207780249173
    • (2007) Curr Pharm Des , vol.13 , pp. 671-686
    • Belfiore, A.1
  • 12
    • 0026637316 scopus 로고
    • Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors
    • Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem (1992) 61:307-30. doi:10.1146/annurev.bi.61.070192.001515
    • (1992) Annu Rev Biochem , vol.61 , pp. 307-330
    • Kornfeld, S.1
  • 13
    • 0025362295 scopus 로고
    • Functionally distinct insulin receptors generated by tissue-specific alternative splicing
    • Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J (1990) 9:2409-13.
    • (1990) EMBO J , vol.9 , pp. 2409-2413
    • Mosthaf, L.1    Grako, K.2    Dull, T.J.3    Coussens, L.4    Ullrich, A.5    McClain, D.A.6
  • 14
    • 0024403208 scopus 로고
    • Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man
    • Moller DE, Yokota A, Caro JF, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol (1989) 3:1263-9. doi:10.1210/mend-3-8-1263
    • (1989) Mol Endocrinol , vol.3 , pp. 1263-1269
    • Moller, D.E.1    Yokota, A.2    Caro, J.F.3    Flier, J.S.4
  • 15
    • 0029835895 scopus 로고    scopus 로고
    • Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3
    • Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest (1996) 98:2612-5. doi:10.1172/JCI119081
    • (1996) J Clin Invest , vol.98 , pp. 2612-2615
    • Harrela, M.1    Koistinen, H.2    Kaprio, J.3    Lehtovirta, M.4    Tuomilehto, J.5    Eriksson, J.6
  • 16
    • 84899586165 scopus 로고    scopus 로고
    • Insulin-like growth factor-II: its role in metabolic and endocrine disease
    • Livingstone C, Borai A. Insulin-like growth factor-II: its role in metabolic and endocrine disease. Clin Endocrinol (Oxf) (2014) 80:773-81. doi:10.1111/cen.12446
    • (2014) Clin Endocrinol (Oxf) , vol.80 , pp. 773-781
    • Livingstone, C.1    Borai, A.2
  • 17
    • 34848845313 scopus 로고    scopus 로고
    • Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
    • Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov (2007) 6:821-33. doi:10.1038/nrd2359
    • (2007) Nat Rev Drug Discov , vol.6 , pp. 821-833
    • Clemmons, D.R.1
  • 18
    • 0032932822 scopus 로고    scopus 로고
    • Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells
    • Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 19:3278-88.
    • (1999) Mol Cell Biol , vol.19 , pp. 3278-3288
    • Frasca, F.1    Pandini, G.2    Scalia, P.3    Sciacca, L.4    Mineo, R.5    Costantino, A.6
  • 20
    • 0036905115 scopus 로고    scopus 로고
    • Cellular actions of the insulin-like growth factor binding proteins
    • Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev (2002) 23:824-54. doi:10.1210/er.2001-0033
    • (2002) Endocr Rev , vol.23 , pp. 824-854
    • Firth, S.M.1    Baxter, R.C.2
  • 22
    • 70350708153 scopus 로고    scopus 로고
    • Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer
    • Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer (2009) 125:2704-10. doi:10.1002/ijc.24609
    • (2009) Int J Cancer , vol.125 , pp. 2704-2710
    • Kabat, G.C.1    Kim, M.2    Caan, B.J.3    Chlebowski, R.T.4    Gunter, M.J.5    Ho, G.Y.6
  • 23
    • 0032499440 scopus 로고    scopus 로고
    • Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
    • Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 351:1393-6. doi:10.1016/S0140-6736(97)10384-1
    • (1998) Lancet , vol.351 , pp. 1393-1396
    • Hankinson, S.E.1    Willett, W.C.2    Colditz, G.A.3    Hunter, D.J.4    Michaud, D.S.5    Deroo, B.6
  • 24
    • 3242884950 scopus 로고    scopus 로고
    • IGF-I and breast cancer: a meta-analysis
    • Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer (2004) 111:418-23. doi:10.1002/ijc.20233
    • (2004) Int J Cancer , vol.111 , pp. 418-423
    • Shi, R.1    Yu, H.2    McLarty, J.3    Glass, J.4
  • 25
    • 0034527640 scopus 로고    scopus 로고
    • Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer
    • Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Baltimore longitudinal study on A. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab (2000) 85:4258-65. doi:10.1210/jcem.85.11.6990
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 4258-4265
    • Harman, S.M.1    Metter, E.J.2    Blackman, M.R.3    Landis, P.K.4    Carter, H.B.5
  • 26
    • 0032559272 scopus 로고    scopus 로고
    • Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study
    • Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 279:563-6. doi:10.1126/science.279.5350.563
    • (1998) Science , vol.279 , pp. 563-566
    • Chan, J.M.1    Stampfer, M.J.2    Giovannucci, E.3    Gann, P.H.4    Ma, J.5    Wilkinson, P.6
  • 28
    • 0033531765 scopus 로고    scopus 로고
    • Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
    • Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 91:620-5. doi:10.1093/jnci/91.7.620
    • (1999) J Natl Cancer Inst , vol.91 , pp. 620-625
    • Ma, J.1    Pollak, M.N.2    Giovannucci, E.3    Chan, J.M.4    Tao, Y.5    Hennekens, C.H.6
  • 29
    • 33745115859 scopus 로고    scopus 로고
    • Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on
    • Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer (2006) 13:273-8. doi:10.1677/erc.1.01219
    • (2006) Endocr Relat Cancer , vol.13 , pp. 273-278
    • Renehan, A.G.1    Harvie, M.2    Howell, A.3
  • 30
    • 79951976645 scopus 로고    scopus 로고
    • Associations of insulin resistance and adiponectin with mortality in women with breast cancer
    • Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol (2011) 29:32-9. doi:10.1200/JCO.2009.26.4473
    • (2011) J Clin Oncol , vol.29 , pp. 32-39
    • Duggan, C.1    Irwin, M.L.2    Xiao, L.3    Henderson, K.D.4    Smith, A.W.5    Baumgartner, R.N.6
  • 31
    • 0036138579 scopus 로고    scopus 로고
    • Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study
    • Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol (2002) 20:42-51. doi:10.1200/JCO.20.1.42
    • (2002) J Clin Oncol , vol.20 , pp. 42-51
    • Goodwin, P.J.1    Ennis, M.2    Pritchard, K.I.3    Trudeau, M.E.4    Koo, J.5    Madarnas, Y.6
  • 32
    • 57749089652 scopus 로고    scopus 로고
    • Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival
    • Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 68:10238-46. doi:10.1158/0008-5472.CAN-08-2755
    • (2008) Cancer Res , vol.68 , pp. 10238-10246
    • Law, J.H.1    Habibi, G.2    Hu, K.3    Masoudi, H.4    Wang, M.Y.5    Stratford, A.L.6
  • 35
    • 82455167825 scopus 로고    scopus 로고
    • Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression
    • Fu P, Ibusuki M, Yamamoto Y, Hayashi M, Murakami K, Zheng S, et al. Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression. Breast Cancer Res Treat (2011) 130:307-17. doi:10.1007/s10549-011-1605-0
    • (2011) Breast Cancer Res Treat , vol.130 , pp. 307-317
    • Fu, P.1    Ibusuki, M.2    Yamamoto, Y.3    Hayashi, M.4    Murakami, K.5    Zheng, S.6
  • 36
    • 80052583009 scopus 로고    scopus 로고
    • Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma
    • Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, et al. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat (2011) 129:725-36. doi:10.1007/s10549-010-1256-6
    • (2011) Breast Cancer Res Treat , vol.129 , pp. 725-736
    • Hartog, H.1    Horlings, H.M.2    van der Vegt, B.3    Kreike, B.4    Ajouaou, A.5    van de Vijver, M.J.6
  • 37
    • 84887272861 scopus 로고    scopus 로고
    • Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study
    • Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, et al. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2013) 22:1984-93. doi:10.1158/1055-9965.EPI-13-0349
    • (2013) Cancer Epidemiol Biomarkers Prev , vol.22 , pp. 1984-1993
    • Zu, K.1    Martin, N.E.2    Fiorentino, M.3    Flavin, R.4    Lis, R.T.5    Sinnott, J.A.6
  • 39
    • 49649101837 scopus 로고    scopus 로고
    • Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer
    • Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res (2008) 14:3022-9. doi:10.1158/1078-0432.CCR-07-1898
    • (2008) Clin Cancer Res , vol.14 , pp. 3022-3029
    • Matsubara, J.1    Yamada, Y.2    Hirashima, Y.3    Takahari, D.4    Okita, N.T.5    Kato, K.6
  • 40
    • 0015296174 scopus 로고
    • Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction
    • Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res (1972) 32:226-32.
    • (1972) Cancer Res , vol.32 , pp. 226-232
    • Heuson, J.C.1    Legros, N.2
  • 41
    • 0015295732 scopus 로고
    • Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats
    • Heuson JC, Legros N, Heimann R. Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res (1972) 32:233-8.
    • (1972) Cancer Res , vol.32 , pp. 233-238
    • Heuson, J.C.1    Legros, N.2    Heimann, R.3
  • 43
    • 0027523609 scopus 로고
    • Insulin dependence of murine T-cell lymphoma. II. Insulin-deficient diabetic mice and mice fed low-energy diet develop resistance to lymphoma growth
    • Sharon R, Pillemer G, Ish-Shalom D, Kalman R, Ziv E, Berry EM, et al. Insulin dependence of murine T-cell lymphoma. II. Insulin-deficient diabetic mice and mice fed low-energy diet develop resistance to lymphoma growth. Int J Cancer (1993) 53:843-9. doi:10.1002/ijc.2910530523
    • (1993) Int J Cancer , vol.53 , pp. 843-849
    • Sharon, R.1    Pillemer, G.2    Ish-Shalom, D.3    Kalman, R.4    Ziv, E.5    Berry, E.M.6
  • 44
  • 45
    • 84855426420 scopus 로고    scopus 로고
    • Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes
    • Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res (2012) 14:R8. doi:10.1186/bcr3089
    • (2012) Breast Cancer Res , vol.14
    • Ferguson, R.D.1    Novosyadlyy, R.2    Fierz, Y.3    Alikhani, N.4    Sun, H.5    Yakar, S.6
  • 46
    • 77950354885 scopus 로고    scopus 로고
    • Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression
    • Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes (2010) 59:686-93. doi:10.2337/db09-1291
    • (2010) Diabetes , vol.59 , pp. 686-693
    • Fierz, Y.1    Novosyadlyy, R.2    Vijayakumar, A.3    Yakar, S.4    LeRoith, D.5
  • 47
    • 76549136489 scopus 로고    scopus 로고
    • Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes
    • Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 70:741-51. doi:10.1158/0008-5472.CAN-09-2141
    • (2010) Cancer Res , vol.70 , pp. 741-751
    • Novosyadlyy, R.1    Lann, D.E.2    Vijayakumar, A.3    Rowzee, A.4    Lazzarino, D.A.5    Fierz, Y.6
  • 48
    • 77951879658 scopus 로고    scopus 로고
    • Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation
    • Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene (2010) 29:2517-27. doi:10.1038/onc.2010.17
    • (2010) Oncogene , vol.29 , pp. 2517-2527
    • Zhang, H.1    Fagan, D.H.2    Zeng, X.3    Freeman, K.T.4    Sachdev, D.5    Yee, D.6
  • 49
    • 0033604523 scopus 로고    scopus 로고
    • The IGF-I receptor in cancer research
    • Baserga R. The IGF-I receptor in cancer research. Exp Cell Res (1999) 253:1-6. doi:10.1006/excr.1999.4667
    • (1999) Exp Cell Res , vol.253 , pp. 1-6
    • Baserga, R.1
  • 50
    • 0027366338 scopus 로고
    • Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor
    • Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A (1993) 90:11217-21. doi:10.1073/pnas.90.23.11217
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 11217-11221
    • Sell, C.1    Rubini, M.2    Rubin, R.3    Liu, J.P.4    Efstratiadis, A.5    Baserga, R.6
  • 51
    • 1042301373 scopus 로고    scopus 로고
    • A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells
    • Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem (2004) 279:5017-24. doi:10.1074/jbc.M305403200
    • (2004) J Biol Chem , vol.279 , pp. 5017-5024
    • Sachdev, D.1    Hartell, J.S.2    Lee, A.V.3    Zhang, X.4    Yee, D.5
  • 52
    • 0032146711 scopus 로고    scopus 로고
    • A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer
    • Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res (1998) 58:3353-61.
    • (1998) Cancer Res , vol.58 , pp. 3353-3361
    • Dunn, S.E.1    Ehrlich, M.2    Sharp, N.J.3    Reiss, K.4    Solomon, G.5    Hawkins, R.6
  • 53
    • 0028920352 scopus 로고
    • Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor
    • Long L, Rubin R, Baserga R, Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res (1995) 55:1006-9.
    • (1995) Cancer Res , vol.55 , pp. 1006-1009
    • Long, L.1    Rubin, R.2    Baserga, R.3    Brodt, P.4
  • 54
    • 0021718287 scopus 로고
    • Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture
    • Myal Y, Shiu RP, Bhaumick B, Bala M. Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. Cancer Res (1984) 44:5486-90.
    • (1984) Cancer Res , vol.44 , pp. 5486-5490
    • Myal, Y.1    Shiu, R.P.2    Bhaumick, B.3    Bala, M.4
  • 55
    • 22744433507 scopus 로고    scopus 로고
    • A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model
    • Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, et al. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene (2005) 24:4736-40. doi:10.1038/sj.onc.1208572
    • (2005) Oncogene , vol.24 , pp. 4736-4740
    • Majeed, N.1    Blouin, M.J.2    Kaplan-Lefko, P.J.3    Barry-Shaw, J.4    Greenberg, N.M.5    Gaudreau, P.6
  • 56
    • 0042090507 scopus 로고    scopus 로고
    • Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors
    • Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res (2003) 63:4384-8.
    • (2003) Cancer Res , vol.63 , pp. 4384-4388
    • Wu, Y.1    Cui, K.2    Miyoshi, K.3    Hennighausen, L.4    Green, J.E.5    Setser, J.6
  • 57
    • 0024460381 scopus 로고
    • Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
    • Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 84:1418-23. doi:10.1172/JCI114315
    • (1989) J Clin Invest , vol.84 , pp. 1418-1423
    • Arteaga, C.L.1    Kitten, L.J.2    Coronado, E.B.3    Jacobs, S.4    Kull F.C, Jr.5    Allred, D.C.6
  • 58
    • 34848903049 scopus 로고    scopus 로고
    • IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor
    • Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res (2007) 13:5549s-55s. doi:10.1158/1078-0432.CCR-07-1109
    • (2007) Clin Cancer Res , vol.13 , pp. 5549s-5555s
    • Rowinsky, E.K.1    Youssoufian, H.2    Tonra, J.R.3    Solomon, P.4    Burtrum, D.5    Ludwig, D.L.6
  • 59
    • 9144234724 scopus 로고    scopus 로고
    • A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo
    • Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 63:8912-21.
    • (2003) Cancer Res , vol.63 , pp. 8912-8921
    • Burtrum, D.1    Zhu, Z.2    Lu, D.3    Anderson, D.M.4    Prewett, M.5    Pereira, D.S.6
  • 60
    • 34548058890 scopus 로고    scopus 로고
    • A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo
    • Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther (2007) 6:2158-67. doi:10.1158/1535-7163.MCT-07-0070
    • (2007) Mol Cancer Ther , vol.6 , pp. 2158-2167
    • Ji, Q.S.1    Mulvihill, M.J.2    Rosenfeld-Franklin, M.3    Cooke, A.4    Feng, L.5    Mak, G.6
  • 61
    • 31544464616 scopus 로고    scopus 로고
    • In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417
    • Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res (2006) 66:362-71. doi:10.1158/0008-5472.CAN-05-1107
    • (2006) Cancer Res , vol.66 , pp. 362-371
    • Haluska, P.1    Carboni, J.M.2    Loegering, D.A.3    Lee, F.Y.4    Wittman, M.5    Saulnier, M.G.6
  • 62
    • 12144285705 scopus 로고    scopus 로고
    • In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase
    • Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell (2004) 5:231-9. doi:10.1016/S1535-6108(04)00051-0
    • (2004) Cancer Cell , vol.5 , pp. 231-239
    • Garcia-Echeverria, C.1    Pearson, M.A.2    Marti, A.3    Meyer, T.4    Mestan, J.5    Zimmermann, J.6
  • 63
    • 34248170187 scopus 로고    scopus 로고
    • Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors
    • Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer (2007) 43:1318-27. doi:10.1016/j.ejca.2007.03.009
    • (2007) Eur J Cancer , vol.43 , pp. 1318-1327
    • Pandini, G.1    Wurch, T.2    Akla, B.3    Corvaia, N.4    Belfiore, A.5    Goetsch, L.6
  • 64
    • 84862575958 scopus 로고    scopus 로고
    • A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer
    • Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, et al. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res (2012) 18:3407-13. doi:10.1158/1078-0432.CCR-12-0482
    • (2012) Clin Cancer Res , vol.18 , pp. 3407-3413
    • Chi, K.N.1    Gleave, M.E.2    Fazli, L.3    Goldenberg, S.L.4    So, A.5    Kollmannsberger, C.6
  • 65
    • 84866707774 scopus 로고    scopus 로고
    • Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer
    • Goto Y, Sekine I, Tanioka M, Shibata T, Tanai C, Asahina H, et al. Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer. Invest New Drugs (2012) 30:1548-56. doi:10.1007/s10637-011-9715-4
    • (2012) Invest New Drugs , vol.30 , pp. 1548-1556
    • Goto, Y.1    Sekine, I.2    Tanioka, M.3    Shibata, T.4    Tanai, C.5    Asahina, H.6
  • 66
    • 66349091290 scopus 로고    scopus 로고
    • Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer
    • Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 27:2516-22. doi:10.1200/JCO.2008.19.9331
    • (2009) J Clin Oncol , vol.27 , pp. 2516-2522
    • Karp, D.D.1    Paz-Ares, L.G.2    Novello, S.3    Haluska, P.4    Garland, L.5    Cardenal, F.6
  • 67
    • 74449085460 scopus 로고    scopus 로고
    • The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival
    • Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene (2010) 29:251-62. doi:10.1038/onc.2009.316
    • (2010) Oncogene , vol.29 , pp. 251-262
    • Sachdev, D.1    Zhang, X.2    Matise, I.3    Gaillard-Kelly, M.4    Yee, D.5
  • 68
    • 65249162840 scopus 로고    scopus 로고
    • Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo
    • Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res (2009) 15:2840-9. doi:10.1158/1078-0432.CCR-08-1401
    • (2009) Clin Cancer Res , vol.15 , pp. 2840-2849
    • Zeng, X.1    Sachdev, D.2    Zhang, H.3    Gaillard-Kelly, M.4    Yee, D.5
  • 69
    • 84874577294 scopus 로고    scopus 로고
    • Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
    • Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, et al. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol (2013) 24:784-91. doi:10.1093/annonc/mds511
    • (2013) Ann Oncol , vol.24 , pp. 784-791
    • Macaulay, V.M.1    Middleton, M.R.2    Protheroe, A.S.3    Tolcher, A.4    Dieras, V.5    Sessa, C.6
  • 70
    • 84876687095 scopus 로고    scopus 로고
    • A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours
    • Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, et al. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer (2013) 49:1799-807. doi:10.1016/j.ejca.2013.01.003
    • (2013) Eur J Cancer , vol.49 , pp. 1799-1807
    • Soria, J.C.1    Massard, C.2    Lazar, V.3    Ozoux, M.L.4    Mery-Mignard, D.5    Deslandes, A.6
  • 71
    • 84929144064 scopus 로고    scopus 로고
    • A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer
    • Lin EH, Lenz HJ, Saleh MN, Mackenzie MJ, Knost JA, Pathiraja K, et al. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med (2014) 3:988-97. doi:10.1002/cam4.263
    • (2014) Cancer Med , vol.3 , pp. 988-997
    • Lin, E.H.1    Lenz, H.J.2    Saleh, M.N.3    Mackenzie, M.J.4    Knost, J.A.5    Pathiraja, K.6
  • 72
    • 84905586194 scopus 로고    scopus 로고
    • A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study
    • Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer (2014) 120:2448-56. doi:10.1002/cncr.28728
    • (2014) Cancer , vol.120 , pp. 2448-2456
    • Pappo, A.S.1    Vassal, G.2    Crowley, J.J.3    Bolejack, V.4    Hogendoorn, P.C.5    Chugh, R.6
  • 73
    • 83355174075 scopus 로고    scopus 로고
    • Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
    • Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 29:4574-80. doi:10.1200/JCO.2011.36.6799
    • (2011) J Clin Oncol , vol.29 , pp. 4574-4580
    • Ramalingam, S.S.1    Spigel, D.R.2    Chen, D.3    Steins, M.B.4    Engelman, J.A.5    Schneider, C.P.6
  • 74
    • 79956205779 scopus 로고    scopus 로고
    • Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models
    • Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther (2011) 337:644-54. doi:10.1124/jpet.110.178400
    • (2011) J Pharmacol Exp Ther , vol.337 , pp. 644-654
    • Beltran, P.J.1    Chung, Y.A.2    Moody, G.3    Mitchell, P.4    Cajulis, E.5    Vonderfecht, S.6
  • 75
    • 66849140937 scopus 로고    scopus 로고
    • AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
    • Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther (2009) 8:1095-105. doi:10.1158/1535-7163.MCT-08-1171
    • (2009) Mol Cancer Ther , vol.8 , pp. 1095-1105
    • Beltran, P.J.1    Mitchell, P.2    Chung, Y.A.3    Cajulis, E.4    Lu, J.5    Belmontes, B.6
  • 76
    • 84925319198 scopus 로고    scopus 로고
    • Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab
    • Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, et al. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol (2015) 10:65-76. doi:10.1007/s11523-014-0315-z
    • (2015) Target Oncol , vol.10 , pp. 65-76
    • Tabernero, J.1    Chawla, S.P.2    Kindler, H.3    Reckamp, K.4    Chiorean, E.G.5    Azad, N.S.6
  • 77
    • 84905968151 scopus 로고    scopus 로고
    • Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
    • Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res (2014) 20:4240-50. doi:10.1158/1078-0432.CCR-13-2752
    • (2014) Clin Cancer Res , vol.20 , pp. 4240-4250
    • Van Cutsem, E.1    Eng, C.2    Nowara, E.3    Swieboda-Sadlej, A.4    Tebbutt, N.C.5    Mitchell, E.6
  • 78
    • 84883823174 scopus 로고    scopus 로고
    • A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
    • Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol (2013) 24:1777-85. doi:10.1093/annonc/mdt057
    • (2013) Ann Oncol , vol.24 , pp. 1777-1785
    • Cohn, A.L.1    Tabernero, J.2    Maurel, J.3    Nowara, E.4    Sastre, J.5    Chuah, B.Y.6
  • 79
    • 84875257995 scopus 로고    scopus 로고
    • Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
    • Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol (2013) 14:228-35. doi:10.1016/S1470-2045(13)70026-3
    • (2013) Lancet Oncol , vol.14 , pp. 228-235
    • Robertson, J.F.1    Ferrero, J.M.2    Bourgeois, H.3    Kennecke, H.4    de Boer, R.H.5    Jacot, W.6
  • 80
    • 84879411446 scopus 로고    scopus 로고
    • A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors
    • Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, et al. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer (2013) 20:383-90. doi:10.1530/ERC-12-0390
    • (2013) Endocr Relat Cancer , vol.20 , pp. 383-390
    • Strosberg, J.R.1    Chan, J.A.2    Ryan, D.P.3    Meyerhardt, J.A.4    Fuchs, C.S.5    Abrams, T.6
  • 81
    • 84862531853 scopus 로고    scopus 로고
    • A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
    • Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr, Rocha-Lima CM, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol (2012) 23:2834-42. doi:10.1093/annonc/mds142
    • (2012) Ann Oncol , vol.23 , pp. 2834-2842
    • Kindler, H.L.1    Richards, D.A.2    Garbo, L.E.3    Garon, E.B.4    Stephenson J.J, Jr.5    Rocha-Lima, C.M.6
  • 82
    • 84863908472 scopus 로고    scopus 로고
    • Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors
    • Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol (2012) 30:1849-56. doi:10.1200/JCO.2011.37.2359
    • (2012) J Clin Oncol , vol.30 , pp. 1849-1856
    • Tap, W.D.1    Demetri, G.2    Barnette, P.3    Desai, J.4    Kavan, P.5    Tozer, R.6
  • 83
    • 84892493984 scopus 로고    scopus 로고
    • A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
    • Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, et al. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol (2014) 60:319-24. doi:10.1016/j.jhep.2013.09.008
    • (2014) J Hepatol , vol.60 , pp. 319-324
    • Abou-Alfa, G.K.1    Capanu, M.2    O'Reilly, E.M.3    Ma, J.4    Chou, J.F.5    Gansukh, B.6
  • 84
    • 84908500883 scopus 로고    scopus 로고
    • Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)
    • Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, et al. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer (2014) 120:2980-5. doi:10.1002/cncr.28744
    • (2014) Cancer , vol.120 , pp. 2980-2985
    • Philip, P.A.1    Goldman, B.2    Ramanathan, R.K.3    Lenz, H.J.4    Lowy, A.M.5    Whitehead, R.P.6
  • 85
    • 84921342727 scopus 로고    scopus 로고
    • Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the children's oncology group
    • Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the children's oncology group. Pediatr Blood Cancer (2014) 62:440-4. doi:10.1002/pbc.25334
    • (2014) Pediatr Blood Cancer , vol.62 , pp. 440-444
    • Wagner, L.M.1    Fouladi, M.2    Ahmed, A.3    Krailo, M.D.4    Weigel, B.5    DuBois, S.G.6
  • 86
    • 84884910107 scopus 로고    scopus 로고
    • An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
    • Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer (2013) 49:3219-28. doi:10.1016/j.ejca.2013.06.010
    • (2013) Eur J Cancer , vol.49 , pp. 3219-3228
    • Schoffski, P.1    Adkins, D.2    Blay, J.Y.3    Gil, T.4    Elias, A.D.5    Rutkowski, P.6
  • 87
    • 84892991988 scopus 로고    scopus 로고
    • Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
    • Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol (2014) 15:191-200. doi:10.1016/S1470-2045(13)70596-5
    • (2014) Lancet Oncol , vol.15 , pp. 191-200
    • Rajan, A.1    Carter, C.A.2    Berman, A.3    Cao, L.4    Kelly, R.J.5    Thomas, A.6
  • 88
    • 84920518981 scopus 로고    scopus 로고
    • Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
    • Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Brana I, et al. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial. Clin Cancer Res (2015) 21:49-59. doi:10.1158/1078-0432.CCR-14-0940
    • (2015) Clin Cancer Res , vol.21 , pp. 49-59
    • Di Cosimo, S.1    Sathyanarayanan, S.2    Bendell, J.C.3    Cervantes, A.4    Stein, M.N.5    Brana, I.6
  • 89
    • 80053525113 scopus 로고    scopus 로고
    • A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    • Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2011) 17:6304-12. doi:10.1158/1078-0432.CCR-10-3336
    • (2011) Clin Cancer Res , vol.17 , pp. 6304-6312
    • Atzori, F.1    Tabernero, J.2    Cervantes, A.3    Prudkin, L.4    Andreu, J.5    Rodriguez-Braun, E.6
  • 90
    • 84983102615 scopus 로고    scopus 로고
    • Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial
    • Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, et al. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Exp Hematol Oncol (2014) 3:26. doi:10.1186/2162-3619-3-26
    • (2014) Exp Hematol Oncol , vol.3 , pp. 26
    • Moran, T.1    Felip, E.2    Keedy, V.3    Borghaei, H.4    Shepherd, F.A.5    Insa, A.6
  • 91
    • 84866521341 scopus 로고    scopus 로고
    • A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
    • Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB, et al. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer (2012) 118:4795-800. doi:10.1002/cncr.27459
    • (2012) Cancer , vol.118 , pp. 4795-4800
    • Reidy-Lagunes, D.L.1    Vakiani, E.2    Segal, M.F.3    Hollywood, E.M.4    Tang, L.H.5    Solit, D.B.6
  • 92
    • 84860339842 scopus 로고    scopus 로고
    • Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor
    • Zeng X, Zhang H, Oh A, Zhang Y, Yee D. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat (2012) 133:117-26. doi:10.1007/s10549-011-1713-x
    • (2012) Breast Cancer Res Treat , vol.133 , pp. 117-126
    • Zeng, X.1    Zhang, H.2    Oh, A.3    Zhang, Y.4    Yee, D.5
  • 93
    • 77952060250 scopus 로고    scopus 로고
    • Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
    • Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem (2009) 1:1153-71. doi:10.4155/fmc.09.89
    • (2009) Future Med Chem , vol.1 , pp. 1153-1171
    • Mulvihill, M.J.1    Cooke, A.2    Rosenfeld-Franklin, M.3    Buck, E.4    Foreman, K.5    Landfair, D.6
  • 94
    • 77958067823 scopus 로고    scopus 로고
    • Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer
    • Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther (2010) 9:2652-64. doi:10.1158/1535-7163.MCT-10-0318
    • (2010) Mol Cancer Ther , vol.9 , pp. 2652-2664
    • Buck, E.1    Gokhale, P.C.2    Koujak, S.3    Brown, E.4    Eyzaguirre, A.5    Tao, N.6
  • 95
    • 84923203848 scopus 로고    scopus 로고
    • Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors
    • Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, et al. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res (2015) 21:693-700. doi:10.1158/1078-0432.CCR-14-0265
    • (2015) Clin Cancer Res , vol.21 , pp. 693-700
    • Jones, R.L.1    Kim, E.S.2    Nava-Parada, P.3    Alam, S.4    Johnson, F.M.5    Stephens, A.W.6
  • 96
    • 84923188816 scopus 로고    scopus 로고
    • A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors in patients with advanced solid tumors
    • Puzanov I, Lindsay CR, Goff LW, Sosman JA, Gilbert J, Berlin J, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors in patients with advanced solid tumors. Clin Cancer Res (2014) 21:701-11. doi:10.1158/1078-0432.CCR-14-0303
    • (2014) Clin Cancer Res , vol.21 , pp. 701-711
    • Puzanov, I.1    Lindsay, C.R.2    Goff, L.W.3    Sosman, J.A.4    Gilbert, J.5    Berlin, J.6
  • 97
    • 84922092092 scopus 로고    scopus 로고
    • A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
    • Bendell JC, Jones SF, Hart L, Spigel DR, Lane CM, Earwood C, et al. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Invest New Drugs (2015) 33:187-93. doi:10.1007/s10637-014-0177-3
    • (2015) Invest New Drugs , vol.33 , pp. 187-193
    • Bendell, J.C.1    Jones, S.F.2    Hart, L.3    Spigel, D.R.4    Lane, C.M.5    Earwood, C.6
  • 98
    • 84907974000 scopus 로고    scopus 로고
    • IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells
    • Singh RK, Gaikwad SM, Jinager A, Chaudhury S, Maheshwari A, Ray P. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Cancer Lett (2014) 354:254-62. doi:10.1016/j.canlet.2014.08.023
    • (2014) Cancer Lett , vol.354 , pp. 254-262
    • Singh, R.K.1    Gaikwad, S.M.2    Jinager, A.3    Chaudhury, S.4    Maheshwari, A.5    Ray, P.6
  • 99
    • 84871368849 scopus 로고    scopus 로고
    • BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer
    • Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther (2012) 11:2644-53. doi:10.1158/1535-7163.MCT-12-0447
    • (2012) Mol Cancer Ther , vol.11 , pp. 2644-2653
    • Awasthi, N.1    Zhang, C.2    Ruan, W.3    Schwarz, M.A.4    Schwarz, R.E.5
  • 100
    • 84863345782 scopus 로고    scopus 로고
    • Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications
    • Feng X, Aleem E, Lin Y, Axelson M, Larsson O, Stromberg T. Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications. Int J Oncol (2012) 40:1251-8. doi:10.3892/ijo.2011.1281
    • (2012) Int J Oncol , vol.40 , pp. 1251-1258
    • Feng, X.1    Aleem, E.2    Lin, Y.3    Axelson, M.4    Larsson, O.5    Stromberg, T.6
  • 101
    • 84859822013 scopus 로고    scopus 로고
    • The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin
    • Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, et al. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. Clin Cancer Res (2012) 18:2230-9. doi:10.1158/1078-0432.CCR-11-1764
    • (2012) Clin Cancer Res , vol.18 , pp. 2230-2239
    • Lemaire, M.1    Fristedt, C.2    Agarwal, P.3    Menu, E.4    Van Valckenborgh, E.5    De Bruyne, E.6
  • 102
    • 73149120253 scopus 로고    scopus 로고
    • BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
    • Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther (2009) 8:3341-9. doi:10.1158/1535-7163.MCT-09-0499
    • (2009) Mol Cancer Ther , vol.8 , pp. 3341-3349
    • Carboni, J.M.1    Wittman, M.2    Yang, Z.3    Lee, F.4    Greer, A.5    Hurlburt, W.6
  • 103
    • 84255192030 scopus 로고    scopus 로고
    • Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer
    • Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res (2011) 71:7597-607. doi:10.1158/0008-5472.CAN-11-1080
    • (2011) Cancer Res , vol.71 , pp. 7597-7607
    • Hou, X.1    Huang, F.2    Macedo, L.F.3    Harrington, S.C.4    Reeves, K.A.5    Greer, A.6
  • 104
    • 79952672340 scopus 로고    scopus 로고
    • Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma
    • Ekman S, Frodin JE, Harmenberg J, Bergman A, Hedlund A, Dahg P, et al. Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol (2011) 50:441-7. doi:10.3109/0284186X.2010.499370
    • (2011) Acta Oncol , vol.50 , pp. 441-447
    • Ekman, S.1    Frodin, J.E.2    Harmenberg, J.3    Bergman, A.4    Hedlund, A.5    Dahg, P.6
  • 105
    • 84919346723 scopus 로고    scopus 로고
    • MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas
    • Zhong H, Fazenbaker C, Breen S, Chen C, Huang J, Morehouse C, et al. MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas. Mol Cancer Ther (2014) 13:2662-73. doi:10.1158/1535-7163.MCT-14-0144
    • (2014) Mol Cancer Ther , vol.13 , pp. 2662-2673
    • Zhong, H.1    Fazenbaker, C.2    Breen, S.3    Chen, C.4    Huang, J.5    Morehouse, C.6
  • 106
    • 84894132629 scopus 로고    scopus 로고
    • Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin
    • Friedbichler K, Hofmann MH, Kroez M, Ostermann E, Lamche HR, Koessl C, et al. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther (2014) 13:399-409. doi:10.1158/1535-7163.MCT-13-0598
    • (2014) Mol Cancer Ther , vol.13 , pp. 399-409
    • Friedbichler, K.1    Hofmann, M.H.2    Kroez, M.3    Ostermann, E.4    Lamche, H.R.5    Koessl, C.6
  • 107
    • 79551547098 scopus 로고    scopus 로고
    • Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth
    • Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res (2011) 71:1029-40. doi:10.1158/0008-5472.CAN-10-2274
    • (2011) Cancer Res , vol.71 , pp. 1029-1040
    • Gao, J.1    Chesebrough, J.W.2    Cartlidge, S.A.3    Ricketts, S.A.4    Incognito, L.5    Veldman-Jones, M.6
  • 108
    • 84922098787 scopus 로고    scopus 로고
    • Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours
    • Iguchi H, Nishina T, Nogami N, Kozuki T, Yamagiwa Y, Yagawa K. Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours. Invest New Drugs (2015) 33:194-200. doi:10.1007/s10637-014-0170-x
    • (2015) Invest New Drugs , vol.33 , pp. 194-200
    • Iguchi, H.1    Nishina, T.2    Nogami, N.3    Kozuki, T.4    Yamagiwa, Y.5    Yagawa, K.6
  • 109
    • 84907917177 scopus 로고    scopus 로고
    • Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors
    • Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, et al. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res (2014) 20:4747-57. doi:10.1158/1078-0432.CCR-14-0114
    • (2014) Clin Cancer Res , vol.20 , pp. 4747-4757
    • Haluska, P.1    Menefee, M.2    Plimack, E.R.3    Rosenberg, J.4    Northfelt, D.5    LaVallee, T.6
  • 110
    • 78650858388 scopus 로고    scopus 로고
    • Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
    • Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer (2011) 104:68-74. doi:10.1038/sj.bjc.6605972
    • (2011) Br J Cancer , vol.104 , pp. 68-74
    • Gualberto, A.1    Hixon, M.L.2    Karp, D.D.3    Li, D.4    Green, S.5    Dolled-Filhart, M.6
  • 111
    • 84881246665 scopus 로고    scopus 로고
    • Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor
    • McCaffery I, Tudor Y, Deng H, Tang R, Suzuki S, Badola S, et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res (2013) 19:4282-9. doi:10.1158/1078-0432.CCR-12-1840
    • (2013) Clin Cancer Res , vol.19 , pp. 4282-4289
    • McCaffery, I.1    Tudor, Y.2    Deng, H.3    Tang, R.4    Suzuki, S.5    Badola, S.6
  • 112
    • 84858334156 scopus 로고    scopus 로고
    • A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
    • Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, et al. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol (2012) 7:419-26. doi:10.1097/JTO.0b013e31823c5b11
    • (2012) J Thorac Oncol , vol.7 , pp. 419-426
    • Weickhardt, A.1    Doebele, R.2    Oton, A.3    Lettieri, J.4    Maxson, D.5    Reynolds, M.6
  • 113
    • 79954575067 scopus 로고    scopus 로고
    • High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy
    • Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res (2011) 17:2314-27. doi:10.1158/1078-0432.CCR-10-1903
    • (2011) Clin Cancer Res , vol.17 , pp. 2314-2327
    • Litzenburger, B.C.1    Creighton, C.J.2    Tsimelzon, A.3    Chan, B.T.4    Hilsenbeck, S.G.5    Wang, T.6
  • 114
    • 58249101005 scopus 로고    scopus 로고
    • The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors
    • Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 69:161-70. doi:10.1158/0008-5472.CAN-08-0835
    • (2009) Cancer Res , vol.69 , pp. 161-170
    • Huang, F.1    Greer, A.2    Hurlburt, W.3    Han, X.4    Hafezi, R.5    Wittenberg, G.M.6
  • 115
    • 68849128275 scopus 로고    scopus 로고
    • Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
    • Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther (2009) 8:2110-21. doi:10.1158/1535-7163.MCT-09-0381
    • (2009) Mol Cancer Ther , vol.8 , pp. 2110-2121
    • Zha, J.1    O'Brien, C.2    Savage, H.3    Huw, L.Y.4    Zhong, F.5    Berry, L.6
  • 116
    • 84858208702 scopus 로고    scopus 로고
    • IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors
    • Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, et al. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res (2012) 18:1808-17. doi:10.1158/1078-0432.CCR-11-1806
    • (2012) Clin Cancer Res , vol.18 , pp. 1808-1817
    • Becker, M.A.1    Hou, X.2    Harrington, S.C.3    Weroha, S.J.4    Gonzalez, S.E.5    Jacob, K.A.6
  • 117
    • 70350218696 scopus 로고    scopus 로고
    • High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)
    • Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One (2009) 4:e7273. doi:10.1371/journal.pone.0007273
    • (2009) PLoS One , vol.4
    • Gong, Y.1    Yao, E.2    Shen, R.3    Goel, A.4    Arcila, M.5    Teruya-Feldstein, J.6
  • 118
    • 84875803717 scopus 로고    scopus 로고
    • Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    • Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol (2013) 14:371-82. doi:10.1016/S1470-2045(13)70049-4
    • (2013) Lancet Oncol , vol.14 , pp. 371-382
    • Schwartz, G.K.1    Tap, W.D.2    Qin, L.X.3    Livingston, M.B.4    Undevia, S.D.5    Chmielowski, B.6
  • 119
    • 84878762419 scopus 로고    scopus 로고
    • Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
    • Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, et al. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat (2012) 136:717-27. doi:10.1007/s10549-012-2260-9
    • (2012) Breast Cancer Res Treat , vol.136 , pp. 717-727
    • Browne, B.C.1    Eustace, A.J.2    Kennedy, S.3    O'Brien, N.A.4    Pedersen, K.5    McDermott, M.S.6
  • 120
    • 84861506168 scopus 로고    scopus 로고
    • Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling
    • Boone DN, Lee AV. Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog (2012) 17:161-73. doi:10.1615/CritRevOncog.v17.i2.30
    • (2012) Crit Rev Oncog , vol.17 , pp. 161-173
    • Boone, D.N.1    Lee, A.V.2
  • 121
    • 79955991871 scopus 로고    scopus 로고
    • 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer
    • McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res (2011) 17:3332-40. doi:10.1158/1078-0432.CCR-10-2274
    • (2011) Clin Cancer Res , vol.17 , pp. 3332-3340
    • McKinley, E.T.1    Bugaj, J.E.2    Zhao, P.3    Guleryuz, S.4    Mantis, C.5    Gokhale, P.C.6
  • 122
    • 84888125634 scopus 로고    scopus 로고
    • Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models
    • Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, et al. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res (2013) 19:6219-29. doi:10.1158/1078-0432.CCR-13-0145
    • (2013) Clin Cancer Res , vol.19 , pp. 6219-6229
    • Flanigan, S.A.1    Pitts, T.M.2    Newton, T.P.3    Kulikowski, G.N.4    Tan, A.C.5    McManus, M.C.6
  • 123
    • 84865676060 scopus 로고    scopus 로고
    • Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity
    • Bao XH, Takaoka M, Hao HF, Wang ZG, Fukazawa T, Yamatsuji T, et al. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity. Anticancer Res (2012) 32:2827-34.
    • (2012) Anticancer Res , vol.32 , pp. 2827-2834
    • Bao, X.H.1    Takaoka, M.2    Hao, H.F.3    Wang, Z.G.4    Fukazawa, T.5    Yamatsuji, T.6
  • 124
    • 42949098453 scopus 로고    scopus 로고
    • Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt
    • Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer (2008) 60:166-74. doi:10.1016/j.lungcan.2007.09.023
    • (2008) Lung Cancer , vol.60 , pp. 166-174
    • Yeh, J.1    Litz, J.2    Hauck, P.3    Ludwig, D.L.4    Krystal, G.W.5
  • 125
    • 84877630250 scopus 로고    scopus 로고
    • Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer
    • Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov (2013) 3:548-63. doi:10.1158/2159-8290.CD-12-0446
    • (2013) Cancer Discov , vol.3 , pp. 548-563
    • Molina-Arcas, M.1    Hancock, D.C.2    Sheridan, C.3    Kumar, M.S.4    Downward, J.5
  • 126
    • 51649091930 scopus 로고    scopus 로고
    • Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis
    • Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 26:4078-85. doi:10.1200/JCO.2007.13.4429
    • (2008) J Clin Oncol , vol.26 , pp. 4078-4085
    • Creighton, C.J.1    Casa, A.2    Lazard, Z.3    Huang, S.4    Tsimelzon, A.5    Hilsenbeck, S.G.6
  • 127
    • 84896040011 scopus 로고    scopus 로고
    • Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
    • Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, et al. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol (2014) 73:467-73. doi:10.1007/s00280-013-2372-x
    • (2014) Cancer Chemother Pharmacol , vol.73 , pp. 467-473
    • Mahadevan, D.1    Sutton, G.R.2    Arteta-Bulos, R.3    Bowden, C.J.4    Miller, P.J.5    Swart, R.E.6
  • 128
    • 84902273066 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study
    • Okusaka T, Ikeda M, Fukutomi A, Kobayashi Y, Shibayama K, Takubo T, et al. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study. Jpn J Clin Oncol (2014) 44:442-7. doi:10.1093/jjco/hyu034
    • (2014) Jpn J Clin Oncol , vol.44 , pp. 442-447
    • Okusaka, T.1    Ikeda, M.2    Fukutomi, A.3    Kobayashi, Y.4    Shibayama, K.5    Takubo, T.6
  • 129
    • 84926126979 scopus 로고    scopus 로고
    • IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination
    • Chitnis MM, Lodhia KA, Aleksic T, Gao S, Protheroe AS, Macaulay VM. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene (2014) 33:5262-73. doi:10.1038/onc.2013.460
    • (2014) Oncogene , vol.33 , pp. 5262-5273
    • Chitnis, M.M.1    Lodhia, K.A.2    Aleksic, T.3    Gao, S.4    Protheroe, A.S.5    Macaulay, V.M.6
  • 130
    • 84927556211 scopus 로고    scopus 로고
    • Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition
    • Lodhia KA, Gao S, Aleksic T, Esashi F, Macaulay VM. Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition. Int J Cancer (2015) 136:2961-6. doi:10.1002/ijc.29327
    • (2015) Int J Cancer , vol.136 , pp. 2961-2966
    • Lodhia, K.A.1    Gao, S.2    Aleksic, T.3    Esashi, F.4    Macaulay, V.M.5
  • 131
    • 84901778615 scopus 로고    scopus 로고
    • Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy
    • Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, et al. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res (2014) 20:2947-58. doi:10.1158/1078-0432.CCR-13-3448
    • (2014) Clin Cancer Res , vol.20 , pp. 2947-2958
    • Beltran, P.J.1    Calzone, F.J.2    Mitchell, P.3    Chung, Y.A.4    Cajulis, E.5    Moody, G.6
  • 132
    • 84880056834 scopus 로고    scopus 로고
    • IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy
    • Ferte C, Loriot Y, Clemenson C, Commo F, Gombos A, Bibault JE, et al. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy. Mol Cancer Ther (2013) 12:1213-22. doi:10.1158/1535-7163.MCT-12-1067
    • (2013) Mol Cancer Ther , vol.12 , pp. 1213-1222
    • Ferte, C.1    Loriot, Y.2    Clemenson, C.3    Commo, F.4    Gombos, A.5    Bibault, J.E.6
  • 133
    • 84927606693 scopus 로고    scopus 로고
    • Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents
    • Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, et al. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. Clin Cancer Res (2015) 21(6):1373-82. doi:10.1158/1078-0432.CCR-14-1688
    • (2015) Clin Cancer Res , vol.21 , Issue.6 , pp. 1373-1382
    • Amaral, A.T.1    Garofalo, C.2    Frapolli, R.3    Manara, M.C.4    Mancarella, C.5    Uboldi, S.6
  • 134
    • 84920824239 scopus 로고    scopus 로고
    • Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo
    • Zhao H, Gu X. Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo. World J Surg Oncol (2014) 12:325. doi:10.1186/1477-7819-12-325
    • (2014) World J Surg Oncol , vol.12 , pp. 325
    • Zhao, H.1    Gu, X.2
  • 135
    • 79961104237 scopus 로고    scopus 로고
    • Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells
    • Isebaert SF, Swinnen JV, McBride WH, Haustermans KM. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells. Int J Radiat Oncol Biol Phys (2011) 81:239-47. doi:10.1016/j.ijrobp.2011.03.030
    • (2011) Int J Radiat Oncol Biol Phys , vol.81 , pp. 239-247
    • Isebaert, S.F.1    Swinnen, J.V.2    McBride, W.H.3    Haustermans, K.M.4
  • 136
    • 10844296820 scopus 로고    scopus 로고
    • Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer
    • Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther (2005) 12:90-100. doi:10.1038/sj.cgt.7700775
    • (2005) Cancer Gene Ther , vol.12 , pp. 90-100
    • Rochester, M.A.1    Riedemann, J.2    Hellawell, G.O.3    Brewster, S.F.4    Macaulay, V.M.5
  • 137
    • 84867788738 scopus 로고    scopus 로고
    • IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer
    • Moreno-Acosta P, Gamboa O, Sanchez de Gomez M, Cendales R, Diaz GD, Romero A, et al. IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer. Anticancer Res (2012) 32:4319-25.
    • (2012) Anticancer Res , vol.32 , pp. 4319-4325
    • Moreno-Acosta, P.1    Gamboa, O.2    Sanchez de Gomez, M.3    Cendales, R.4    Diaz, G.D.5    Romero, A.6
  • 138
    • 73349099049 scopus 로고    scopus 로고
    • Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
    • Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 27:5800-7. doi:10.1200/JCO.2009.23.6745
    • (2009) J Clin Oncol , vol.27 , pp. 5800-5807
    • Tolcher, A.W.1    Sarantopoulos, J.2    Patnaik, A.3    Papadopoulos, K.4    Lin, C.C.5    Rodon, J.6
  • 139
    • 35348815620 scopus 로고    scopus 로고
    • Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
    • Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 13:5834-40. doi:10.1158/1078-0432.CCR-07-1118
    • (2007) Clin Cancer Res , vol.13 , pp. 5834-5840
    • Haluska, P.1    Shaw, H.M.2    Batzel, G.N.3    Yin, D.4    Molina, J.R.5    Molife, L.R.6
  • 140
    • 84859406516 scopus 로고    scopus 로고
    • Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2
    • Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther (2012) 11:649-59. doi:10.1158/1535-7163.MCT-11-0575
    • (2012) Mol Cancer Ther , vol.11 , pp. 649-659
    • Bid, H.K.1    Zhan, J.2    Phelps, D.A.3    Kurmasheva, R.T.4    Houghton, P.J.5
  • 141
    • 77953973648 scopus 로고    scopus 로고
    • Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
    • Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 107:10791-8. doi:10.1073/pnas.0914076107
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 10791-10798
    • Ulanet, D.B.1    Ludwig, D.L.2    Kahn, C.R.3    Hanahan, D.4
  • 142
    • 65549161522 scopus 로고    scopus 로고
    • Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma
    • Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res (2009) 69:2443-52. doi:10.1158/0008-5472.CAN-08-2645
    • (2009) Cancer Res , vol.69 , pp. 2443-2452
    • Avnet, S.1    Sciacca, L.2    Salerno, M.3    Gancitano, G.4    Cassarino, M.F.5    Longhi, A.6
  • 143
    • 84880336001 scopus 로고    scopus 로고
    • Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression
    • Bowers LW, Cavazos DA, Maximo IX, Brenner AJ, Hursting SD, deGraffenried LA. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. Breast Cancer Res (2013) 15:R59. doi:10.1186/bcr3453
    • (2013) Breast Cancer Res , vol.15
    • Bowers, L.W.1    Cavazos, D.A.2    Maximo, I.X.3    Brenner, A.J.4    Hursting, S.D.5    deGraffenried, L.A.6
  • 144
    • 79551576468 scopus 로고    scopus 로고
    • Mechanisms of endocrine resistance in breast cancer
    • Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med (2011) 62:233-47. doi:10.1146/annurev-med-070909-182917
    • (2011) Annu Rev Med , vol.62 , pp. 233-247
    • Osborne, C.K.1    Schiff, R.2
  • 145
    • 69249137029 scopus 로고    scopus 로고
    • Biological determinants of endocrine resistance in breast cancer
    • Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 9:631-43. doi:10.1038/nrc2713
    • (2009) Nat Rev Cancer , vol.9 , pp. 631-643
    • Musgrove, E.A.1    Sutherland, R.L.2
  • 146
    • 57149137029 scopus 로고    scopus 로고
    • Crosstalk between IGF1R and estrogen receptor signaling in breast cancer
    • Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2008) 13:423-9. doi:10.1007/s10911-008-9098-0
    • (2008) J Mammary Gland Biol Neoplasia , vol.13 , pp. 423-429
    • Fagan, D.H.1    Yee, D.2
  • 147
    • 80155131176 scopus 로고    scopus 로고
    • A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer
    • Fox EM, Miller TW, Balko JM, Kuba MG, Sanchez V, Smith RA, et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 71:6773-84. doi:10.1158/0008-5472.CAN-11-1295
    • (2011) Cancer Res , vol.71 , pp. 6773-6784
    • Fox, E.M.1    Miller, T.W.2    Balko, J.M.3    Kuba, M.G.4    Sanchez, V.5    Smith, R.A.6
  • 148
    • 77950691907 scopus 로고    scopus 로고
    • Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines
    • Chakraborty AK, Welsh A, Digiovanna MP. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat (2010) 120:327-35. doi:10.1007/s10549-009-0382-5
    • (2010) Breast Cancer Res Treat , vol.120 , pp. 327-335
    • Chakraborty, A.K.1    Welsh, A.2    Digiovanna, M.P.3
  • 149
    • 84863584930 scopus 로고    scopus 로고
    • Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment
    • Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res (2012) 72:3372-80. doi:10.1158/0008-5472.CAN-12-0684
    • (2012) Cancer Res , vol.72 , pp. 3372-3380
    • Fagan, D.H.1    Uselman, R.R.2    Sachdev, D.3    Yee, D.4
  • 150
    • 80054921787 scopus 로고    scopus 로고
    • Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment
    • Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer (2011) 18:565-77. doi:10.1530/ERC-10-0046
    • (2011) Endocr Relat Cancer , vol.18 , pp. 565-577
    • Drury, S.C.1    Detre, S.2    Leary, A.3    Salter, J.4    Reis-Filho, J.5    Barbashina, V.6
  • 151
    • 80052225259 scopus 로고    scopus 로고
    • Insulin increases de novo steroidogenesis in prostate cancer cells
    • Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, et al. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res (2011) 71:5754-64. doi:10.1158/0008-5472.CAN-10-2470
    • (2011) Cancer Res , vol.71 , pp. 5754-5764
    • Lubik, A.A.1    Gunter, J.H.2    Hendy, S.C.3    Locke, J.A.4    Adomat, H.H.5    Thompson, V.6
  • 152
    • 84857656268 scopus 로고    scopus 로고
    • Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)
    • Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol (2012) 23:2153-61. doi:10.1093/annonc/mdr574
    • (2012) Ann Oncol , vol.23 , pp. 2153-2161
    • Schmitz, S.1    Kaminsky-Forrett, M.C.2    Henry, S.3    Zanetta, S.4    Geoffrois, L.5    Bompas, E.6
  • 153
    • 54249117292 scopus 로고    scopus 로고
    • Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors
    • Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res (2008) 68:8322-32. doi:10.1158/0008-5472.CAN-07-6720
    • (2008) Cancer Res , vol.68 , pp. 8322-8332
    • Buck, E.1    Eyzaguirre, A.2    Rosenfeld-Franklin, M.3    Thomson, S.4    Mulvihill, M.5    Barr, S.6
  • 154
    • 0036141447 scopus 로고    scopus 로고
    • Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling
    • Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res (2002) 62:200-7.
    • (2002) Cancer Res , vol.62 , pp. 200-207
    • Chakravarti, A.1    Loeffler, J.S.2    Dyson, N.J.3
  • 155
    • 84887606851 scopus 로고    scopus 로고
    • Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways
    • van der Meel R, Oliveira S, Altintas I, Heukers R, Pieters EH, van Bergen en Henegouwen PM, et al. Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways. Mol Pharm (2013) 10:3717-27. doi:10.1021/mp400212v
    • (2013) Mol Pharm , vol.10 , pp. 3717-3727
    • van der Meel, R.1    Oliveira, S.2    Altintas, I.3    Heukers, R.4    Pieters, E.H.5    van Bergen en Henegouwen, P.M.6
  • 156
    • 54249157471 scopus 로고    scopus 로고
    • Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
    • Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res (2008) 68:8039-48. doi:10.1158/0008-5472.CAN-08-1712
    • (2008) Cancer Res , vol.68 , pp. 8039-8048
    • Cao, L.1    Yu, Y.2    Darko, I.3    Currier, D.4    Mayeenuddin, L.H.5    Wan, X.6
  • 157
    • 32944457518 scopus 로고    scopus 로고
    • mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 66:1500-8. doi:10.1158/0008-5472.CAN-05-2925
    • (2006) Cancer Res , vol.66 , pp. 1500-1508
    • O'Reilly, K.E.1    Rojo, F.2    She, Q.B.3    Solit, D.4    Mills, G.B.5    Smith, D.6
  • 158
    • 84875230967 scopus 로고    scopus 로고
    • Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
    • Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer (2013) 108:826-30. doi:10.1038/bjc.2013.46
    • (2013) Br J Cancer , vol.108 , pp. 826-830
    • Naing, A.1    Lorusso, P.2    Fu, S.3    Hong, D.4    Chen, H.X.5    Doyle, L.A.6
  • 159
    • 84860506226 scopus 로고    scopus 로고
    • Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
    • Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 18:2625-31. doi:10.1158/1078-0432.CCR-12-0061
    • (2012) Clin Cancer Res , vol.18 , pp. 2625-2631
    • Naing, A.1    LoRusso, P.2    Fu, S.3    Hong, D.S.4    Anderson, P.5    Benjamin, R.S.6
  • 160
    • 79951816312 scopus 로고    scopus 로고
    • Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
    • Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res (2011) 17:871-9. doi:10.1158/1078-0432.CCR-10-2621
    • (2011) Clin Cancer Res , vol.17 , pp. 871-879
    • Quek, R.1    Wang, Q.2    Morgan, J.A.3    Shapiro, G.I.4    Butrynski, J.E.5    Ramaiya, N.6
  • 161
    • 84891002824 scopus 로고    scopus 로고
    • Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone
    • Nordstrand A, Lundholm M, Larsson A, Lerner UH, Widmark A, Wikstrom P. Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone. Cancer Microenviron (2013) 6:231-40. doi:10.1007/s12307-013-0129-z
    • (2013) Cancer Microenviron , vol.6 , pp. 231-240
    • Nordstrand, A.1    Lundholm, M.2    Larsson, A.3    Lerner, U.H.4    Widmark, A.5    Wikstrom, P.6
  • 162
    • 84863801971 scopus 로고    scopus 로고
    • Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer
    • Shao M, Hollar S, Chambliss D, Schmitt J, Emerson R, Chelladurai B, et al. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Mol Cancer Ther (2012) 11:1576-86. doi:10.1158/1535-7163.MCT-11-0961
    • (2012) Mol Cancer Ther , vol.11 , pp. 1576-1586
    • Shao, M.1    Hollar, S.2    Chambliss, D.3    Schmitt, J.4    Emerson, R.5    Chelladurai, B.6
  • 163
    • 84906058215 scopus 로고    scopus 로고
    • IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer
    • Bruchim I, Sarfstein R, Reiss A, Flescher E, Werner H. IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer. Cancer Lett (2014) 352:214-9. doi:10.1016/j.canlet.2014.06.013
    • (2014) Cancer Lett , vol.352 , pp. 214-219
    • Bruchim, I.1    Sarfstein, R.2    Reiss, A.3    Flescher, E.4    Werner, H.5
  • 164
    • 84896690513 scopus 로고    scopus 로고
    • Prevalence of childhood and adult obesity in the United States, 2011-2012
    • Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA (2014) 311:806-14. doi:10.1001/jama.2014.732
    • (2014) JAMA , vol.311 , pp. 806-814
    • Ogden, C.L.1    Carroll, M.D.2    Kit, B.K.3    Flegal, K.M.4
  • 165
    • 84906882822 scopus 로고    scopus 로고
    • Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013
    • Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet (2014) 384:766-81. doi:10.1016/S0140-6736(14)60460-8
    • (2014) Lancet , vol.384 , pp. 766-781
    • Ng, M.1    Fleming, T.2    Robinson, M.3    Thomson, B.4    Graetz, N.5    Margono, C.6
  • 166
    • 0027092522 scopus 로고
    • Abdominal obesity and the metabolic syndrome
    • Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med (1992) 24:465-8. doi:10.3109/07853899209166997
    • (1992) Ann Med , vol.24 , pp. 465-468
    • Bjorntorp, P.1
  • 167
    • 84879621442 scopus 로고    scopus 로고
    • AMPK, insulin resistance, and the metabolic syndrome
    • Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest (2013) 123:2764-72. doi:10.1172/JCI67227
    • (2013) J Clin Invest , vol.123 , pp. 2764-2772
    • Ruderman, N.B.1    Carling, D.2    Prentki, M.3    Cacicedo, J.M.4
  • 168
    • 76449104378 scopus 로고    scopus 로고
    • Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome?
    • Ruan W, Lai M. Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol (2010) 47:5-14. doi:10.1007/s00592-009-0142-3
    • (2010) Acta Diabetol , vol.47 , pp. 5-14
    • Ruan, W.1    Lai, M.2
  • 170
    • 84859132868 scopus 로고    scopus 로고
    • Applying what we know to accelerate cancer prevention
    • Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci Transl Med (2012) 4:127rv4. doi:10.1126/scitranslmed.3003218
    • (2012) Sci Transl Med , vol.4
    • Colditz, G.A.1    Wolin, K.Y.2    Gehlert, S.3
  • 171
    • 0035901090 scopus 로고    scopus 로고
    • Inflammation and cancer: back to Virchow?
    • Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-45. doi:10.1016/S0140-6736(00)04046-0
    • (2001) Lancet , vol.357 , pp. 539-545
    • Balkwill, F.1    Mantovani, A.2
  • 172
    • 0037180757 scopus 로고    scopus 로고
    • Inflammation and cancer
    • Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420:860-7. doi:10.1038/nature01322
    • (2002) Nature , vol.420 , pp. 860-867
    • Coussens, L.M.1    Werb, Z.2
  • 173
    • 0032090186 scopus 로고    scopus 로고
    • Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus
    • Foltz CJ, Fox JG, Cahill R, Murphy JC, Yan L, Shames B, et al. Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter (1998) 3:69-78. doi:10.1046/j.1523-5378.1998.08006.x
    • (1998) Helicobacter , vol.3 , pp. 69-78
    • Foltz, C.J.1    Fox, J.G.2    Cahill, R.3    Murphy, J.C.4    Yan, L.5    Shames, B.6
  • 174
    • 79960820132 scopus 로고    scopus 로고
    • The growing challenge of obesity and cancer: an inflammatory issue
    • Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci (2011) 1229:45-52. doi:10.1111/j.1749-6632.2011.06096.x
    • (2011) Ann N Y Acad Sci , vol.1229 , pp. 45-52
    • Harvey, A.E.1    Lashinger, L.M.2    Hursting, S.D.3
  • 175
    • 79955862214 scopus 로고    scopus 로고
    • Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland
    • Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) (2011) 4:329-46. doi:10.1158/1940-6207.CAPR-10-0381
    • (2011) Cancer Prev Res (Phila) , vol.4 , pp. 329-346
    • Subbaramaiah, K.1    Howe, L.R.2    Bhardwaj, P.3    Du, B.4    Gravaghi, C.5    Yantiss, R.K.6
  • 176
    • 77951918926 scopus 로고    scopus 로고
    • Macrophages, inflammation, and insulin resistance
    • Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol (2010) 72:219-46. doi:10.1146/annurev-physiol-021909-135846
    • (2010) Annu Rev Physiol , vol.72 , pp. 219-246
    • Olefsky, J.M.1    Glass, C.K.2
  • 177
    • 84866250761 scopus 로고    scopus 로고
    • Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women
    • Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2:356-65. doi:10.1158/2159-8290.CD-11-0241
    • (2012) Cancer Discov , vol.2 , pp. 356-365
    • Subbaramaiah, K.1    Morris, P.G.2    Zhou, X.K.3    Morrow, M.4    Du, B.5    Giri, D.6
  • 178
    • 79960082421 scopus 로고    scopus 로고
    • Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer
    • Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 4:1021-9. doi:10.1158/1940-6207.CAPR-11-0110
    • (2011) Cancer Prev Res (Phila) , vol.4 , pp. 1021-1029
    • Morris, P.G.1    Hudis, C.A.2    Giri, D.3    Morrow, M.4    Falcone, D.J.5    Zhou, X.K.6
  • 179
    • 60149088612 scopus 로고    scopus 로고
    • Inflammation in obesity-related diseases
    • O'Rourke RW. Inflammation in obesity-related diseases. Surgery (2009) 145:255-9. doi:10.1016/j.surg.2008.08.038
    • (2009) Surgery , vol.145 , pp. 255-259
    • O'Rourke, R.W.1
  • 180
    • 47349129465 scopus 로고    scopus 로고
    • Obesity and cancer: pathophysiological and biological mechanisms
    • Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem (2008) 114:71-83. doi:10.1080/13813450801954303
    • (2008) Arch Physiol Biochem , vol.114 , pp. 71-83
    • Renehan, A.G.1    Roberts, D.L.2    Dive, C.3
  • 181
    • 33745298519 scopus 로고    scopus 로고
    • Nuclear factor-kappaB in cancer development and progression
    • Karin M. Nuclear factor-kappaB in cancer development and progression. Nature (2006) 441:431-6. doi:10.1038/nature04870
    • (2006) Nature , vol.441 , pp. 431-436
    • Karin, M.1
  • 182
    • 82955237238 scopus 로고    scopus 로고
    • A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs
    • McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, et al. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene (2011) 30:4910-20. doi:10.1038/onc.2011.197
    • (2011) Oncogene , vol.30 , pp. 4910-4920
    • McKinsey, E.L.1    Parrish, J.K.2    Irwin, A.E.3    Niemeyer, B.F.4    Kern, H.B.5    Birks, D.K.6
  • 183
    • 79952012742 scopus 로고    scopus 로고
    • Molecular targets of phytochemicals for cancer prevention
    • Lee KW, Bode AM, Dong Z. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer (2011) 11:211-8. doi:10.1038/nrc3017
    • (2011) Nat Rev Cancer , vol.11 , pp. 211-218
    • Lee, K.W.1    Bode, A.M.2    Dong, Z.3
  • 184
    • 67650944993 scopus 로고    scopus 로고
    • Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
    • Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 460:392-5. doi:10.1038/nature08221
    • (2009) Nature , vol.460 , pp. 392-395
    • Harrison, D.E.1    Strong, R.2    Sharp, Z.D.3    Nelson, J.F.4    Astle, C.M.5    Flurkey, K.6
  • 185
    • 84876438500 scopus 로고    scopus 로고
    • The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001
    • De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, et al. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog (2013) 52:446-58. doi:10.1002/mc.21878
    • (2013) Mol Carcinog , vol.52 , pp. 446-458
    • De Angel, R.E.1    Conti, C.J.2    Wheatley, K.E.3    Brenner, A.J.4    Otto, G.5    Degraffenried, L.A.6
  • 186
    • 84860903290 scopus 로고    scopus 로고
    • Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity
    • Nogueira LM, Dunlap SM, Ford NA, Hursting SD. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer (2012) 19:57-68. doi:10.1530/ERC-11-0213
    • (2012) Endocr Relat Cancer , vol.19 , pp. 57-68
    • Nogueira, L.M.1    Dunlap, S.M.2    Ford, N.A.3    Hursting, S.D.4
  • 187
    • 79960085339 scopus 로고    scopus 로고
    • Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer
    • Lashinger LM, Malone LM, Brown GW, Daniels EA, Goldberg JA, Otto G, et al. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. Cancer Prev Res (Phila) (2011) 4:1041-51. doi:10.1158/1940-6207.CAPR-11-0023
    • (2011) Cancer Prev Res (Phila) , vol.4 , pp. 1041-1051
    • Lashinger, L.M.1    Malone, L.M.2    Brown, G.W.3    Daniels, E.A.4    Goldberg, J.A.5    Otto, G.6
  • 188
    • 84859117806 scopus 로고    scopus 로고
    • Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity
    • Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 335:1638-43. doi:10.1126/science.1215135
    • (2012) Science , vol.335 , pp. 1638-1643
    • Lamming, D.W.1    Ye, L.2    Katajisto, P.3    Goncalves, M.D.4    Saitoh, M.5    Stevens, D.M.6
  • 189
    • 84866322945 scopus 로고    scopus 로고
    • Investigating metformin for cancer prevention and treatment: the end of the beginning
    • Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov (2012) 2:778-90. doi:10.1158/2159-8290.CD-12-0263
    • (2012) Cancer Discov , vol.2 , pp. 778-790
    • Pollak, M.N.1
  • 191
    • 78649302320 scopus 로고    scopus 로고
    • Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis
    • Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 3:1451-61. doi:10.1158/1940-6207.CAPR-10-0157
    • (2010) Cancer Prev Res (Phila) , vol.3 , pp. 1451-1461
    • Decensi, A.1    Puntoni, M.2    Goodwin, P.3    Cazzaniga, M.4    Gennari, A.5    Bonanni, B.6
  • 192
    • 68449094325 scopus 로고    scopus 로고
    • The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    • Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 52:1766-77. doi:10.1007/s00125-009-1440-6
    • (2009) Diabetologia , vol.52 , pp. 1766-1777
    • Currie, C.J.1    Poole, C.D.2    Gale, E.A.3
  • 193
    • 79151478459 scopus 로고    scopus 로고
    • Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
    • Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat (2011) 126:215-20. doi:10.1007/s10549-010-1224-1
    • (2011) Breast Cancer Res Treat , vol.126 , pp. 215-220
    • Goodwin, P.J.1    Stambolic, V.2    Lemieux, J.3    Chen, B.E.4    Parulekar, W.R.5    Gelmon, K.A.6
  • 194
    • 0038360735 scopus 로고    scopus 로고
    • A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women
    • Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab (2003) 88:1617-23. doi:10.1210/jc.2002-021480
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 1617-1623
    • Brehm, B.J.1    Seeley, R.J.2    Daniels, S.R.3    D'Alessio, D.A.4
  • 195
    • 84861925298 scopus 로고    scopus 로고
    • Ketogenic diet and other dietary treatments for epilepsy
    • Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev (2012) 3:CD001903. doi:10.1002/14651858.CD001903.pub2
    • (2012) Cochrane Database Syst Rev , vol.3
    • Levy, R.G.1    Cooper, P.N.2    Giri, P.3
  • 196
  • 197
    • 84930937889 scopus 로고    scopus 로고
    • Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature
    • Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab (2015) 3:3. doi:10.1186/s40170-015-0129-1
    • (2015) Cancer Metab , vol.3 , pp. 3
    • Schwartz, K.1    Chang, H.T.2    Nikolai, M.3    Pernicone, J.4    Rhee, S.5    Olson, K.6
  • 198
    • 79959860165 scopus 로고    scopus 로고
    • A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation
    • Ho VW, Leung K, Hsu A, Luk B, Lai J, Shen SY, et al. A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res (2011) 71:4484-93. doi:10.1158/0008-5472.CAN-10-3973
    • (2011) Cancer Res , vol.71 , pp. 4484-4493
    • Ho, V.W.1    Leung, K.2    Hsu, A.3    Luk, B.4    Lai, J.5    Shen, S.Y.6
  • 199
    • 84875208817 scopus 로고    scopus 로고
    • The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model
    • Caso J, Masko EM, Ii JA, Poulton SH, Dewhirst M, Pizzo SV, et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate (2013) 73:449-54. doi:10.1002/pros.22586
    • (2013) Prostate , vol.73 , pp. 449-454
    • Caso, J.1    Masko, E.M.2    Ii, J.A.3    Poulton, S.H.4    Dewhirst, M.5    Pizzo, S.V.6
  • 200
    • 68949183226 scopus 로고    scopus 로고
    • The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model
    • Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, et al. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (2009) 2:557-65. doi:10.1158/1940-6207.CAPR-08-0188
    • (2009) Cancer Prev Res , vol.2 , pp. 557-565
    • Mavropoulos, J.C.1    Buschemeyer, W.C.2    Tewari, A.K.3    Rokhfeld, D.4    Pollak, M.5    Zhao, Y.6
  • 201
    • 77956465178 scopus 로고    scopus 로고
    • The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma
    • Stafford P, Abdelwahab MG, Kim Y, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (2010) 7:74. doi:10.1186/1743-7075-7-74
    • (2010) Nutr Metab , vol.7 , pp. 74
    • Stafford, P.1    Abdelwahab, M.G.2    Kim, Y.3    Preul, M.C.4    Rho, J.M.5    Scheck, A.C.6
  • 202
    • 44649088303 scopus 로고    scopus 로고
    • Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides
    • Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer (2008) 8:122. doi:10.1186/1471-2407-8-122
    • (2008) BMC Cancer , vol.8 , pp. 122
    • Otto, C.1    Kaemmerer, U.2    Illert, B.3    Muehling, B.4    Pfetzer, N.5    Wittig, R.6
  • 203
    • 84860521413 scopus 로고    scopus 로고
    • The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma
    • Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One (2012) 7:e36197. doi:10.1371/journal.pone.0036197
    • (2012) PLoS One , vol.7
    • Abdelwahab, M.G.1    Fenton, K.E.2    Preul, M.C.3    Rho, J.M.4    Lynch, A.5    Stafford, P.6
  • 204
    • 79955381447 scopus 로고    scopus 로고
    • Lack of dietary carbohydrates induces hepatic growth hormone (GH) resistance in rats
    • Bielohuby M, Sawitzky M, Stoehr BJ, Stock P, Menhofer D, Ebensing S, et al. Lack of dietary carbohydrates induces hepatic growth hormone (GH) resistance in rats. Endocrinology (2011) 152:1948-60. doi:10.1210/en.2010-1423
    • (2011) Endocrinology , vol.152 , pp. 1948-1960
    • Bielohuby, M.1    Sawitzky, M.2    Stoehr, B.J.3    Stock, P.4    Menhofer, D.5    Ebensing, S.6
  • 205
    • 0024209333 scopus 로고
    • A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model
    • Tisdale MJ, Brennan RA. A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model. Br J Cancer (1988) 58:580-3. doi:10.1038/bjc.1988.263
    • (1988) Br J Cancer , vol.58 , pp. 580-583
    • Tisdale, M.J.1    Brennan, R.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.